Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00075192 · ClinicalTrials.gov registry record · Phase 1
CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00075192: Completed Phase 1 study, sponsored by AstraZeneca.
NCT00075192 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00075192, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization, patients will receive study treatment for three cycles (one cycle is defined as 28 days). After completion of three cycles, patients will undergo a prostatectomy and pathology assessments will be completed at a central laboratory, the Armed Forces Institute of Pathology (AFIP) in Washington, DC.
Interventions
- DRUG CP-675,206 and leuprolide acetate and bicalutamide
- DRUG leuprolide acetate and bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 1 |
What the finished NCT00075192 record still lists
NCT00075192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which CP-675,206 and leuprolide acetate and bicalutamide is the first listed.
NCT00075192 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00075192 about?
NCT00075192 is a clinical study titled "CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer". This is a multi-center, open label, randomized study. Patients will be randomized to one of the following arms with an allocation ratio of 3:1, respectively: Arm A: CP-675,206 + neoadjuvant hormone therapy (NHT) OR Arm B: neoadjuvant hormone therapy. After randomization, patients will receive study ...
What is the current status of trial NCT00075192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2004-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00075192?
The interventions under investigation include: CP-675,206 and leuprolide acetate and bicalutamide (DRUG), leuprolide acetate and bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00075192?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00075192's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia